Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
The BMA junior doctors committee has voted to go to a ballot for industrial action in early January due to the government’s continual failure to value them and "reverse years of pay erosion".
The number of people living with type 1 diabetes is expected to double by 2040 to between 13.5 and 17.5 million people, according to a new modelling study published in The Lancet Diabetes and Endocrinology.
The risk of potentially life-threatening blood clots after Covid-19 infection lasts for at least 49 weeks and people with only mild or moderate disease are also affected, according to a new research.
Researchers have discovered a strict relationship between hot temperatures and weight loss in heart failure patients, an indicator that their condition is worsening.
Ending smoking in England would have the biggest impact on closing the 'cancer inequality gap' between the most affluent individuals and the rest of the country, according to new analysis from Cancer Research UK.
As the NHS faces the biggest crisis in its history, we have seen three health secretaries swing through the doors of the Department of Health and Social Care this year promising to put things right. Who is Thérèse Coffey and what can we…
The NHS has introduced additional measures to help battle long Covid, including the creation of one stop shops and mobile clinics, which will offer a range of checks.
Nearly 25,000 men were checked for prostate cancer in March 2022, the highest number on record, following a campaign launched by the NHS and Prostate Cancer in February.
Men with higher adiposity (body fat) are at increased risk of fatal prostate cancer, according to new research.
Warmer temperatures during the night-time in summer may be linked with an increase in cardiovascular death in men in their early 60s, according to a study published in BMJ Open.
A new report is calling for the government to take stronger action to tackle the leading risk factors for ill health following years of slow, uneven and disjointed policy making.
Adding abiraterone to the standard treatment for prostate cancer could halve the risk of death in some patients and improve outcomes for thousands of people every year, according to a study led by UCL.
New researched published in The Lancet Oncology suggests that men who have a high genetic risk for certain cancers through 'Lynch syndrome' could benefit from regular testing for prostate cancer.
The Scottish Medicines Consortium (SMC) has approved the use of the drug olaparib for some people in Scotland with a type of advanced prostate cancer.